Patents Assigned to University of Zurich
  • Patent number: 6960559
    Abstract: The present invention relates to genes and their encoded proteins which regulate neurite growth and the diagnostic and therapeutic use of such proteins (termed herein neurite growth regulatory factors). The proteins of the present invention include metalloproteases associated with glioblastoma cells. The metalloproteases of the invention have value in the treatment of nerve damage and of degenerative disorders of the nervous system.
    Type: Grant
    Filed: October 1, 1997
    Date of Patent: November 1, 2005
    Assignee: University of Zurich
    Inventors: Martin E. Schwab, Pierenrico W. Caroni, Paolo A. Paganetti
  • Patent number: 6878804
    Abstract: Template-fixed ?-hairpin loop mimetics comprising a template corresponding to one of the structures (a), (b), (c), (d), (e), (f), (g), (h) and a template-fixed chain of 4 to 20 ?-amino acid residues which, if their ?-C atom is asymmetric, have L-configuration can be manufactured by a novel process which is based on a mixed solid- and solution phase synthetic strategy. If desired, this process can be modified to give the enantiomers of these template-fixed ?-hairpin loop mimetics. These enantiomers are novel compounds, and many of said template-fixed ?-hairpin loop mimetics themselves are also novel compounds. The template-fixed ?-hairpin loop mimetics and their enantiomers can mimick flat surfaces of proteins and thus be used to probe large surface protein-protein interactions. Accordingly they can serve as lead finding tools for protein targets where it is difficult to find small-molecular-weight lead compounds.
    Type: Grant
    Filed: August 30, 1999
    Date of Patent: April 12, 2005
    Assignees: University of Zurich, Polyphor AG
    Inventors: John A. Robinson, Daniel Obrecht
  • Patent number: 6815540
    Abstract: The present invention relates to the modification of immunoglobulin superfamily (IgSF) domains, IgSF fragments and fusion proteins thereof, especially to the modification of antibody derivatives, so as to improve their solubility, and hence the yield, and ease of handling. The inventors have found that this can be achieved by making the region which comprised the interface with domains adjoined to said IgSF domain in a larger fragment or a full IgSF protein, and which becomes exposed in the IgSF domain, more hydrophilic by modification. The present invention describes DNA sequences encoding modified IgSF domains or fragments and fusion proteins thereof, vectors and hosts containing these DNA sequences, IgSF domains or fragments or fusion proteins obtainable by expressing said DNA sequences in suitable expression systems, and a method for modifying IgSF domains, so as to improve their solubility, expressibility and ease of handling.
    Type: Grant
    Filed: January 15, 1999
    Date of Patent: November 9, 2004
    Assignee: University of Zurich
    Inventors: Andreas Plückthun, Lars Nieba, Annemarie Honegger
  • Patent number: 6780621
    Abstract: The present invention relates to fatty acid 13-hydroperoxide lyase protein from guava (Psidium guajava) and the gene encoding the protein. Expression systems for recombinant guava 13-hydroperoxide lyase and methods of using recombinant guava 13-hydroperoxide lyase for the production of green notes are provided.
    Type: Grant
    Filed: January 9, 2002
    Date of Patent: August 24, 2004
    Assignees: Firmenich SA, Vanderbilt University, The University of Zurich
    Inventors: Ian Michael Whitehead, Alan John Slusarenko, Urs Wäspi, Duncan James Horatio Gaskin, Alan Richard Brash, Nathalie Tijet
  • Publication number: 20040152627
    Abstract: The present invention relates to pharmaceutical compositions containing a synergistic amount of at least one bone morphogenetic protein (BMP) and a synergistic amount of at least one pyrrolidone optionally in a pharmaceutically acceptable carrier, such as a biodegradable polymer. The present invention further relates to methods of treating orthopaedic and dental, including periodontal, diseases by simultaneously administering a synergistic amount of at least one bone morphogenetic protein (BMP) and a synergistic amount of at least one pyrrolidone optionally in a pharmaceutically acceptable carrier to patients in need of such treatment.
    Type: Application
    Filed: January 30, 2003
    Publication date: August 5, 2004
    Applicant: The University of Zurich
    Inventor: Franz Ernst Weber
  • Patent number: 6630317
    Abstract: The present invention relates to a method for obtaining nucleic acid sequences encoding (poly)peptides which increase the expression yields of periplasmic proteins in functional form upon co-expression of said (poly)peptides and said periplasmic proteins. The invention also provides a method for the identification of said (poly)peptides. Furthermore, the present invention relates to a method for increasing the expression yields of periplasmic proteins in functional form by co-expressing (poly)peptides, for example Skp, FkpA, or a homolog of Skp or FkpA, in bacteria.
    Type: Grant
    Filed: May 1, 2000
    Date of Patent: October 7, 2003
    Assignee: University of Zurich
    Inventors: Andreas Plückthun, Hendrick Bothmann
  • Patent number: 6589741
    Abstract: The present invention relates to methods for identifying nucleic acid molecules encoding (poly)peptides that interact with target molecules. The method of the present invention is particularly characterized by an in vitro translation step under conditions that allow formation of polysomes in the presence of antisense oligonucleotides complementary to the tag-coding sequence of ssrA-RNA. The present invention further relates to kits that are useful for carrying out the method of the invention.
    Type: Grant
    Filed: September 14, 2001
    Date of Patent: July 8, 2003
    Assignee: University of Zurich
    Inventors: Andreas Plückthun, Jozef Hanes, Lutz Jermutus
  • Patent number: 6573090
    Abstract: The present invention relates to an enhanced and simplified herpes virus amplicon packaging system. The packaging system comprises a herpes virus amplicon vector and a packaging vector. In one embodiment, the packaging vector comprises a bacterial artificial chromosome (BAC) containing the HSV-1 genome. The packaging vector contains an intact pac site but is otherwise rendered packaging defective. The packaging vector can be rendered packaging defective by inserting nucleotides into the pac site, or by otherwise interfering with the capsid's ability to close, for example, by increasing the size of the DNA fragment upon which the herpes virus genome is cloned. This system can be used to package a wide range of nucleotide sequences (e.g., a therapeutic or antigenic gene) into an empty herpes virus particle taking advantage of the large transgene capacity of herpes viruses. This system can also be used as a vaccine to induce protective immunity against HSV-1, or other complex pathogens.
    Type: Grant
    Filed: December 9, 1999
    Date of Patent: June 3, 2003
    Assignees: The General Hospital Corporation, University Medical Centre St. Radboud of the University of Nijmegen, University of Zurich, The Walter & Eliza Hall Institute of Medical Research
    Inventors: Xandra O. Breakefield, E. Antonio Chiocca, Yoshinaga Saeki, Cornel Fraefel, Kurt Tobler, Mathias Ackermann, Mark Suter, Gosse J. Adema, Ken Shortman
  • Publication number: 20030045474
    Abstract: The present invention relates to a pharmaceutical composition containing a mixture of stable folding variants of recombinant bone morphogenic proteins (rBMPs) and its use in therapy, especially in the treatment of orthopaedic and dental patients. Specifically, the present invention relates to a pharmaceutical composition containing a mixture of stable folding variants of at least two rBMPs or their monomers or mutants in a suitable carrier system.
    Type: Application
    Filed: July 2, 2002
    Publication date: March 6, 2003
    Applicant: University of Zurich
    Inventors: Hermann Sailer, Franz Weber
  • Patent number: 6348315
    Abstract: The present invention relates to methods for identifying nucleic acid molecules encoding (poly)peptides that interact with target molecules. The method of the present invention is particularly characterized by an in vitro translation step under conditions that allow formation of polysomes in the presence of antisense oligonucleotides complementary to the tag-coding sequence of ssrA-RNA. The present invention further relates to kits that are useful for carrying out the method of the invention.
    Type: Grant
    Filed: October 22, 1999
    Date of Patent: February 19, 2002
    Assignee: University of Zürich, Assignee for Josef Hanes
    Inventors: Andreas Plückthun, Jozef Hanes, Lutz Jermutus
  • Patent number: 6200794
    Abstract: The present invention relates to fatty acid 13-hydroperoxide lyase protein from guava (Psidium guajava) and the gene encoding the protein. Expression systems for recombinant guava 13-hydroperoxide lyase and methods of using recombinant guava 13-hydroperoxide lyase for the production of green notes are provided.
    Type: Grant
    Filed: May 13, 1998
    Date of Patent: March 13, 2001
    Assignees: Fimenrich SA, University of Zurich, Vanderbilt University
    Inventors: Ian Michael Whitehead, Alan John Slusarenko, Urs Wäspi, Duncan James Horatio Gaskin, Alan Richard Brash, Nathalie Tijet
  • Patent number: 5117692
    Abstract: In order to measure a layer in the volume of a reflective structure, a transducer matrix emits at least one sonic or ultrasonic wave packet which coherently impinges on the layer. The echo signals at each element of the transducer matrix are processed separately, on the basis of determined distances between transducer elements and volume elements, and signals corresponding to the echo of each volume element on all the transducer elements of the matrix are calculated by correlation. By emitting two or more wave packets and evaluating the resulting phase or frequency difference therebetween, a two-dimensional velocity field of the structure in the layer can also be determined.
    Type: Grant
    Filed: January 19, 1990
    Date of Patent: June 2, 1992
    Assignee: Institute of Biomedical Engineering and Medical Informatics of the University of Zurich and the Swiss Federal Institute of Technology Zurich
    Inventor: Urs Moser